Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.
Salliot C, Dougados M, Gossec L. · 2009
Read Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. by Salliot C, Dougados M, Gossec L. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2596305.txt.
Introduction
Salliot, Dougados, and Gossec pooled randomised trials in 2009. They checked whether three newer biological drugs for rheumatoid arthritis raise the risk of serious infections. Those are infections that threaten life or need hospital care. Tumour necrosis factor blockers, the older biologics, are known to raise this risk. The team analysed twelve placebo-controlled trials of rituximab, abatacept, and anakinra found through systematic searching to October 2007.
Across 745 rituximab, 1,960 abatacept, and 2,062 anakinra patients, neither rituximab nor abatacept showed a significant rise in serious infections against placebo. High-dose anakinra, at 100 milligrams daily or more, looked different. Its odds ratio reached 3.40 against placebo, and 9.63 against the low dose. The authors flag those figures as a real concern, especially in patients with other illnesses. They call for large practice-based studies to confirm the profile.
Catalog record
| CREATOR | Salliot C, Dougados M, Gossec L. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials By C Salliot, M Dougados, L Gossec Published in: Annals of the Rheumatic Diseases DOI: 10.1136/ard.2007.083188 ABSTRACT Abstract Background: Tumour necrosis factor α blockers in rheumatoid arthritis are known to increase the risk of serious infections defined as life-threatening, requiring hospitalisation or intravenous antibiotics. Recently, new biological agents have become available. Their safety is an important issue. Purpose: To assess if biological agents, ie rituximab, abatacept and anakinra increase the risk of serious infections in patients with rheumatoid arthritis in published randomised controlled trials. Data source: A systematic review of the literature using PUBMED, EMBASE, Cochrane library and abstracts databases (American College of Rheumatology and European League Against Rheumatism annual meetings) was performed up to October 2007. This search was completed with data from the Food and Drug Administration, the European Agency for the Evaluation of Medicinal Products and manufacturers. Data extraction: Three fixed-effect meta-analyses were performed to compare serious infection rates between each biological agent and placebo. Pooled odds ratios (ORs) were calculated, using the Mantel–Haenszel method with a continuity correction. Data synthesis: Twelve randomised controlled trials with data concerning serious infections were analysed (three for rituximab, five for abatacept and four for anakinra). They included 745 patients, 1960 patients, 2062 patients and 2112 patients treated by rituximab, abatacept, anakinra and placebo respectively. The overall pooled ORs did not reveal a statistically significant increased risk of serious infection for abatacept and rituximab; this risk was increased for high doses of anakinra (⩾100 mg daily) versus low dose and placebo (ORs = 9.63 (95% CI, 1.31 to 70.91) and 3.40 (95% CI, 1.11 to 10.46) respectively). Conclusions: These meta-analyses did not reveal a significant increase in the risk of serious infections during rituximab or abatacept treatments in patients with rheumatoid arthritis; however, high doses of anakinra may increase this risk, especially when patients have comorbidity factors. Large studies must be performed to confirm this safety profile in daily practice. Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterised by chronic polyarticular synovial inflammation that may lead to irreversible joint damage with disability and deformity. This joint inflammation is a result of the excessive production by activated T cells of pro-inflammatory cytokines, such as tumour necrosis factor (TNF) α, interleukin (IL)-1, IL-6, and the stimulation of immunoglobulin production by B cells. The conventional treatment of RA combines corticosteroids and disease-modifying anti-rheumatic drugs (DMARDs), in particular, methotrexate. However, RA may remain active despite such treatments. Since 1997, new treatments based on biological agents have demonstrated their efficacy in RA. Biotherapies have different therapeutic targets and some are aimed against pro-inflammatory cytokines: three TNF-α blockers are available, infliximab, etanercept and adalimumab1–7 and one IL-1 receptor antagonist, anakinra.8 Down-regulation of T cell activation is achieved by the recombinant human fusion protein CTLA-4-immunoglobulin G (abatacept)9 and B cells are the selective target of the chimeric anti-CD20 monoclonal antibody (rituximab).10 Before the biotherapy era, it was reported that the incidence rate of infections in the RA population was nearly twice as high as in matched non-RA controls.11 This is thought to be related to the disease itself, which alters immunological functions, decreases mobility and causes skin defects, and also to immunosuppressive drugs, in particular concomitant use of steroids.11 12 In post-marketing surveillance and observational studies of TNF-α blockers, serious infections (defined as life-threatening or requiring intravenous antibiotics or hospitalisation) appear to be the most frequent adverse event with a prevalence of 6–18% and an incidence rate of approximately 6 per 100 patient-years.13–15 Furthermore, case–control studies, conducted in routine daily practice, showed that the risk of serious infections was two- to three-fold higher in patients receiving TNF-α blockers compared with those not treated with such treatment.13–16 Thus it is clear that TNF-α blockers can increase immunosuppression in patients with RA and induce the emergence of serious infections. Meta-analysis is an interesting method to detect such a risk of a relatively rare event: a recent meta-analysis of randomised placebo-controlled trials of monoclonal anti-TNF-α antibodies (infliximab, adalimumab) found a pooled odds ratio (OR) for serious infections of 2.0 (95% confidence interval (CI), 1.3 to 3.1) in TNF-α blocker treated patients.17 However, individually, the trials had failed to demonstrate this increased risk of serious infections. For other biological agents that may interfere with the immune response (rituximab, anakinra, abatacept), data on serious infections are lacking. The purpose of this study was to assess if these biotherapies increased the risk of serious infections in patients with RA, by performing a meta-analysis of data published to date. METHODS For each biological agent, a meta-analysis was conducted according to the Cochrane Collaboration guidelines.18 Study selection A systematic literature search of the literature published up to December 2007 was performed in PUBMED, EMBASE and Cochrane library databases; without limitation of years of publication or journal, using the followings key-words: “rheumatoid arthritis”, “abatacept”, “rituximab”, “anakinra”, “clinical controlled trials”, “clinical trials”, “randomised controlled trials”, “clinical trials phase II, III, IV”. We also included congress abstracts of American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) meetings from 2004 to 2006, because we assumed that any abstract published prior to 2004 had been published in a formal full-length work. Moreover, to complete our search with unpublished data, the Food and Drug Administration (FDA), the European Agency for the Evaluation of Medicinal Products (EMEA) and the manufacturers (Roche, Amgen and Bristol-Myers Squibb) were contacted. The trials were initially selected on the basis of their titles and abstract. The inclusion criteria were randomised placebo-controlled trials in adult patients with RA according to ACR criteria.19 The publications had to be written in English, French or Spanish. The patients had to be randomised to receive placebo or one of the three biological agents (rituximab, anakinra and abatacept), as monotherapy or with concomitant biological or non-biological DMARDs. Reviews and articles reporting trials that were not placebo-controlled were excluded. Data collection One investigator (CS) selected the articles and collected the data, using a predetermined form. The following methodological features were collected: simple or double blinding, intention-to-treat-analysis or not, number of participants who completed the follow-up. For each trial, demographic characteristics (percentage female, mean age), RA features and its duration, treatment allocation (with doses and duration), concomitant treatments (DMARDs, corticosteroids, non-steroid anti-inflammatory drugs) and duration of follow-up were collected. In the literature, a serious infection is usually defined as life-threatening, requiring intravenous antibiotics or hospitalisations.1 5 6 This definition was also used here; if another definition of serious infections was given in the trials, it was also recorded. The number of patients with at least one serious infection in placebo and biological agent groups were collected. When available, the characteristics of infections (localisation, organism and outcome) were noted. Statistical analysis For each biological agent, a fixed-effects meta-analysis of dichotomous outcomes was performed. This model has a superior performance to random-effect models when pooling trials with few or no events, such as serious infections.20 Because serious infections were rare events and some trials were small, the Mantel–Haenszel method was chosen with a continuity correction when there was no serious infection observed in one study arm of a trial. The Mantel–Haenszel method was used to estimate